CL2008000134A1 - Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed - Google Patents

Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed

Info

Publication number: CL2008000134A1
Authority: CL; Chile
Prior art keywords: compound; methyl; benzamida; butil; hydroxi
Prior art date: 2007-01-18

Application number

CL200800134A

Other languages

English (en)

Inventor

Hans-Michael Eggenweiller

Michael Wolf

Hans-Peter Buchstaller

Cristian Sirrenberg

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-18

Filing date

2008-01-16

Publication date

2008-05-16

2008-01-16 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2008-05-16 Publication of CL2008000134A1 publication Critical patent/CL2008000134A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)

CL200800134A 2007-01-18 2008-01-16 Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed CL2008000134A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102007002715A DE102007002715A1 (de)	2007-01-18	2007-01-18	Triazolderivat

Publications (1)

Publication Number	Publication Date
CL2008000134A1 true CL2008000134A1 (es)	2008-05-16

Family

ID=39345628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800134A CL2008000134A1 (es)	2007-01-18	2008-01-16	Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed

Country Status (22)

Country	Link
US (1)	US8816070B2 (es)
EP (1)	EP2102175B1 (es)
JP (1)	JP5266253B2 (es)
KR (1)	KR20090101381A (es)
CN (1)	CN101583605B (es)
AR (1)	AR064951A1 (es)
AU (1)	AU2007344512B2 (es)
BR (1)	BRPI0720956A2 (es)
CA (1)	CA2675737C (es)
CL (1)	CL2008000134A1 (es)
DE (1)	DE102007002715A1 (es)
EA (1)	EA015366B1 (es)
EC (1)	ECSP099586A (es)
ES (1)	ES2455504T3 (es)
MX (1)	MX2009007479A (es)
MY (1)	MY151452A (es)
NZ (1)	NZ579069A (es)
PE (1)	PE20090051A1 (es)
TW (1)	TW200838502A (es)
UA (1)	UA98320C2 (es)
WO (1)	WO2008086857A1 (es)
ZA (1)	ZA200905700B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2193135A1 (en) *	2007-08-13	2010-06-09	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
AR077405A1 (es)	2009-07-10	2011-08-24	Sanofi Aventis	Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr)	2009-09-03	2011-11-25	Sanofi Aventis	Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
RS53716B1 (sr) *	2009-10-19	2015-04-30	Synta Pharmaceuticals Corp.	Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
EP2560640A1 (en)	2010-04-19	2013-02-27	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
DE102010024338A1 (de)	2010-06-18	2011-12-22	Merck Patent Gmbh	Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid
AU2011308403B2 (en) *	2010-10-01	2014-08-21	Taisho Pharmaceutical Co., Ltd.	1,2,4-triazolone derivative
US20130338178A1 (en) *	2011-02-02	2013-12-19	The Trustees Of Princeton University	Sirtuin modulators as inhibitors of cytomegalovirus
AU2012332424A1 (en)	2011-11-02	2014-06-05	Synta Pharmaceuticals Corp.	Combination therapy of Hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
CN106478531B (zh) *	2015-08-25	2019-06-28	南京华威医药科技集团有限公司	2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸中间体
EP3794009A1 (en) *	2018-05-14	2021-03-24	Reata Pharmaceuticals, Inc.	Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
CN115006395B (zh) *	2022-04-29	2023-03-14	佛山病原微生物研究院	一种xl888在制备用于抗腺病毒感染的药物中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968921A (en)	1997-10-24	1999-10-19	Orgegon Health Sciences University	Compositions and methods for promoting nerve regeneration
AU3378599A (en)	1998-04-03	1999-10-25	University Of Pittsburgh	Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2003523313A (ja)	1999-03-12	2003-08-05	アメリカ合衆国	シャペロン蛋白質の阻害方法
EP1265913A4 (en)	2000-03-24	2004-07-14	Univ Duke	CHARACTERIZATION OF THE INTERACTION BETWEEN GRP94 AND A LIGAND, AND CLEANING, SCREENING AND THERAPEUTIC PROCEDURES RELATING TO IT
WO2002002123A1 (en)	2000-06-29	2002-01-10	Trustees Of Boston University	Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
EP1322325A4 (en)	2000-07-20	2004-09-15	Merck & Co Inc	INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
EP1322307B1 (en)	2000-07-28	2011-09-28	Sloan-Kettering Institute For Cancer Research	Methods for treating cell proliferative disorders and viral infections
US7439359B2 (en)	2000-11-02	2008-10-21	Sloan-Kettering Institute For Cancer Research	Small molecule compositions for binding to hsp90
US7553979B2 (en)	2001-11-09	2009-06-30	Conforma Therapeutics Corporation	HSP90-inhibiting zearalanol compounds and methods of producing and using same
JP4399265B2 (ja)	2001-12-21	2010-01-13	ヴァーナリス（ケンブリッジ）リミテッド	３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0228417D0 (en)	2002-12-05	2003-01-08	Cancer Rec Tech Ltd	Pyrazole compounds
GB0229618D0 (en)	2002-12-19	2003-01-22	Cancer Rec Tech Ltd	Pyrazole compounds
US7691838B2 (en)	2003-05-30	2010-04-06	Kosan Biosciences Incorporated	Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054589A1 (en)	2003-05-30	2005-03-10	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020534A1 (en)	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en)	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050026893A1 (en)	2003-05-30	2005-02-03	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en)	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054625A1 (en)	2003-05-30	2005-03-10	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
EP1817295B1 (en) *	2004-11-18	2012-11-07	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
DE102005007304A1 (de)	2005-02-17	2006-08-24	Merck Patent Gmbh	Triazolderivate

2007
- 2007-01-18 DE DE102007002715A patent/DE102007002715A1/de not_active Withdrawn
- 2007-12-11 ES ES07856537.1T patent/ES2455504T3/es active Active
- 2007-12-11 EP EP07856537.1A patent/EP2102175B1/de active Active
- 2007-12-11 NZ NZ579069A patent/NZ579069A/en not_active IP Right Cessation
- 2007-12-11 AU AU2007344512A patent/AU2007344512B2/en not_active Ceased
- 2007-12-11 BR BRPI0720956-8A patent/BRPI0720956A2/pt not_active IP Right Cessation
- 2007-12-11 CN CN2007800499639A patent/CN101583605B/zh not_active Expired - Fee Related
- 2007-12-11 MX MX2009007479A patent/MX2009007479A/es active IP Right Grant
- 2007-12-11 US US12/523,387 patent/US8816070B2/en active Active
- 2007-12-11 WO PCT/EP2007/010775 patent/WO2008086857A1/de not_active Ceased
- 2007-12-11 UA UAA200908637A patent/UA98320C2/ru unknown
- 2007-12-11 JP JP2009545828A patent/JP5266253B2/ja not_active Expired - Fee Related
- 2007-12-11 CA CA2675737A patent/CA2675737C/en active Active
- 2007-12-11 EA EA200900913A patent/EA015366B1/ru not_active IP Right Cessation
- 2007-12-11 KR KR1020097016991A patent/KR20090101381A/ko not_active Withdrawn
- 2007-12-11 MY MYPI20092959 patent/MY151452A/en unknown
2008
- 2008-01-16 CL CL200800134A patent/CL2008000134A1/es unknown
- 2008-01-17 TW TW097101845A patent/TW200838502A/zh unknown
- 2008-01-17 PE PE2008000150A patent/PE20090051A1/es not_active Application Discontinuation
- 2008-01-18 AR ARP080100223A patent/AR064951A1/es unknown
2009
- 2009-08-17 EC EC2009009586A patent/ECSP099586A/es unknown
- 2009-08-17 ZA ZA200905700A patent/ZA200905700B/xx unknown

Also Published As

Publication number	Publication date
US8816070B2 (en)	2014-08-26
DE102007002715A1 (de)	2008-07-24
MY151452A (en)	2014-05-30
ZA200905700B (en)	2010-05-26
AU2007344512A1 (en)	2008-07-24
MX2009007479A (es)	2009-08-13
EP2102175A1 (de)	2009-09-23
EA015366B1 (ru)	2011-06-30
TW200838502A (en)	2008-10-01
WO2008086857A1 (de)	2008-07-24
JP5266253B2 (ja)	2013-08-21
NZ579069A (en)	2011-09-30
PE20090051A1 (es)	2009-01-26
AR064951A1 (es)	2009-05-06
UA98320C2 (en)	2012-05-10
ES2455504T3 (es)	2014-04-15
AU2007344512B2 (en)	2012-11-01
KR20090101381A (ko)	2009-09-25
CA2675737C (en)	2015-03-24
EP2102175B1 (de)	2014-01-22
EA200900913A1 (ru)	2009-12-30
CN101583605B (zh)	2013-06-19
CA2675737A1 (en)	2008-07-24
JP2010516639A (ja)	2010-05-20
BRPI0720956A2 (pt)	2014-03-18
ECSP099586A (es)	2009-09-29
CN101583605A (zh)	2009-11-18
US20100113542A1 (en)	2010-05-06

Publication	Publication Date	Title
CL2008000134A1 (es)	2008-05-16	Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed
BRPI0809977A2 (pt)	2014-10-07	Uso de um composto, compostos e composição farmacêutica que o contém
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0809667A2 (pt)	2014-10-07	Composto, medicamento e composição farmacêutica que o contém e uso do composto
UY30610A1 (es)	2008-05-02	Moduladores de mglur5
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0815079A2 (pt)	2015-02-03	Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
BRPI0809346A2 (pt)	2014-10-07	Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CL2008003690A1 (es)	2009-12-18	Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
BRPI0906576A2 (pt)	2015-07-07	Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007003645A1 (es)	2008-06-20	Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
BRPI0819232A2 (pt)	2016-11-01	composto heterocíclico e composição farmacêutica do mesmo
CL2007000918A1 (es)	2008-02-08	Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
CL2007003232A1 (es)	2008-06-27	Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto
CL2008002041A1 (es)	2009-01-09	Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
BRPI0907892A2 (pt)	2015-07-28	Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
BRPI0717369A2 (pt)	2014-10-07	Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0810399A2 (pt)	2014-11-04	Composto, composição farmacêutica que o contém e uso do mesmo